We only have this paper's title and publication details.
Read it at the sourceAnswers are grounded in this paper and cite their sources.
This analysis examines venetoclax with hypomethylating agents in relapsed/refractory AML, suggesting potential benefits for transplants.
No takes yet. Share an insight, caveat, or question.
Verdeyen et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: